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Background: The aim of this study was to evaluate the time trend of seropositivity of Helicobacter pylori (H. pylori)
over the period of 13 years in an asymptomatic Korean population, and investigate associated risk factors.
Methods: This cross-sectional nationwide multicentre study surveyed anti-H. pylori IgG antibodies in 19,272 health
check-up subjects (aged [greater than and equal to]16 years) in 2011. Risk factors for H. pylori infection were
investigated using logistic regression. Seropositivity in asymptomatic subjects without H. pylori eradication was
compared between the years 1998 and 2005. Birth cohort effects were also evaluated.
Results: After exclusion of subjects with a history of H. pylori eradication therapy (n = 3,712, 19.3%) and gastric
symptoms (n = 4,764, 24.7%), the seroprevalence of H. pylori infection was 54.4% in 10,796 subjects. This was
significantly lower than the seroprevalence of 59.6% in 2005 and that of 66.9% in 1998, and this decrease of
seropositivity of H. pylori became widespread across all ages and in most areas of the country. This decreasing trend
could be explained by cohort analysis. All younger birth cohorts had a lower seroprevalence of H. pylori than older
birth cohorts at the same age. Decreased seroprevalence within the same birth cohorts also accounted for this
phenomenon. Clinical risk factors of H. pylori infection were higher cholesterol level ([greater than and equal to]
240 mg/dl) (OR = 1.33; 95% CI = 1.14-1.54), male gender, older age, low income, and residence in a rural area.
Conclusions: A decreasing trend of H. pylori seroprevalence due to a birth cohort effect requires further studies on
its related human host factors as well as socio-economic and hygienic factors. In addition, the relationship between
H. pylori infection and high cholesterol level needs more investigation regarding underlying pathogenesis.
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Helicobacter pylori (H. pylori), a cause of peptic ulcer dis-
ease, gastric adenocarcinoma, and low-grade gastric mu-
cosa associated lymphoid tissue (MALT) lymphoma [1]
has been falling due to improved sanitation and better
living conditions [2,3]. However, its prevalence is
reported to be still high, especially in Asia including* Correspondence: nayoungkim49@empal.com
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reproduction in any medium, provided the orSouth Korea. From the public health perspective, obser-
vation of prevalence trends and confirmation of risk fac-
tors for H. pylori infection are important to establish
health policies to prevent H. pylori related diseases.
There are many studies regarding the prevalence and
risk factors of H. pylori infection, and older age was
commonly considered as the main risk factor [4,5]. One
study mentioned that adults have a continuous risk of
H. pylori infection, resulting in increased seroprevalence
during lifetime as a function of age [6]. However, this
does not mean that young people have a higher sero-
prevalence when they get older, showing that cross sec-
tional presentation does not necessarily give an accurate. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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on lifetime trends for H. pylori seroprevalence [7,8].
In South Korea, previous study also indicated a decreas-
ing pattern of H. pylori infection during a time period be-
tween 1998 and 2005 [9]. As Korea is in a dynamic state
of progression from a developing country into a developed
country, it may be valuable to evaluate the seroprevalence
of H. pylori in Korea. In accordance with this point of
view, the aim of this study was to investigate the trends of
seropositivity of H. pylori in asymptomatic Korean sub-
jects over 16 years of age together with cohort effects be-
tween the years 1998 and 2011, and to find factors related
to H. pylori infection.
Methods
Study population
This is a cross-sectional nationwide multicentre study of
adult subjects aged 16 years or older who visited healthcare
centers for routine health check-up between January and
December 2011 in South Korea. The subjects were en-
rolled prospectively in 2011 under a predefined protocol.
The institutions participating in this study were healthcare
centers located in Seoul and in the seven provinces of
South Korea.
Informed consent was obtained from each subject. All
subjects were invited to answer the questionnaire which
was the same as previous study’s [9] under the supervision
of a well-trained interviewer. The questionnaire included
information regarding demographic data (i.e. age, sex, and
residence), socioeconomic data (i.e. monthly income and
education level), medical history (such as H. pylori eradi-
cation therapy, history of gastric operation, and family his-
tory of gastric cancer (GC)), and upper gastrointestinal
(GI) symptoms (such as indigestion, bloating, epigastric
soreness, regurgitation, or heartburn), that persisted for at
least one month within the last 3 years.
Subjects were categorized into 3 education levels: low
(middle school graduate or less), middle (high school
graduate or university dropout), and high (university
graduate or graduate of a postgraduate course). Monthly
family income was classed as 3 groups: low household
income (< US $ 3,000 per month), middle income (US
$ 3,000 to 10,000 per month), and high income (> US
$ 10,000 per month).
Clinical and laboratory evaluations
Anthropometric measurements (weight and height) were
done by trained nurses using a standardized protocol.
Blood samples were obtained from the antecubital vein
in the morning after overnight fasting, and serum samples
were separated after centrifugation. Serum cholesterol, tri-
glyceride, and fasting glucose were measured by an auto-
matic analyser, Alisei® (Seac, Pomezia, Italy). To compare
these results according to seropositivity of H. Pylori, wecategorized the level of total cholesterol (TC) as normal
(≤240 mg/dl) and abnormal (>240 mg/dl), trigryceride
(TG) as ≤150 mg/dl and >150 mg/dl, and fasting glucose
as ≤100 mg/dl and >100 mg/dl, respectively.
Anti-H. pylori IgG was measured using H. pylori-EIA-
Well in Healthcare System Gangnam Center and
Genedia H. pylori ELISA at the remaining centers using
the same kits as those in the previous studies [9,10].
Genedia H. pylori ELISA, developed from Korean H. pyl-
ori strains showed a sensitivity of 97.8% and a specificity
of 92% [11]. H. pylori-EIA-Well showed a sensitivity of
95.6% and a specificity of 97.8% when Genedia H. pylori
ELISA was used as the gold standard [9].
Statistical analysis
Evaluation of risk factors of each group according to
eradication of H. pylori
Demographic and clinical information were summarized
by descriptive statistics. To investigate risk factors for
H. pylori seropositivity and influential factors having a his-
tory of H. pylori eradication, multivariable logistic regres-
sion was used. A significance level of p < 0.05 was used for
all analyses.
Comparison of trends of seroprevalence of H. pylori in
1998, 2005, and 2011
Trends of seroprevalence of H. pylori were compared
using the published data of 1998 [10] and 2005 [9]. For
this comparison, study subjects in each time period were
restricted to asymptomatic subjects without a history of
H. pylori eradication and gastric operation. For statistical
comparison of trends of seroprevalence of H. pylori in
1998, 2005, and 2011, the Cochrane-Armitage trend test,
which is a modified Pearson chi-square test to examine
the association between a binary outcome and a variable
with multiple categories with order, was conducted.
Analysis of cohort effects
In addition, the seroprevalence of H. pylori by birth cohort
group was also drawn. To examine birth cohort effects,
we created synthetic cohorts from the successive cross-
sectional data of 1998, 2005, and 2011. For this analysis,
relevant raw data in 1998 and 2005 were obtained from
the authors and reconstructed for the analysis of birth co-
hort. Data from 1998 was considered to be those in 1999
because the successive cross-sectional data should span
with same interval. The interval of three cross-sectional
data was 6 years. The aggregate birth cohort from 1930 to
1972 was restructured into 8 groups using the standard
approach for cohort analysis [12]. In detail, a birth cohort
was obtained by subtracting age from year (i.e. Birth co-
hort of 1974.5 (birth cohort of 1972–77) = Year of 1998 –
Age of 24.5 (22–27 years old)). For example, people aged
22–27 years in 1998 (considered as data in 1999), those
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2011 were considered to be in the same birth cohort, born
between 1972 and 1977. Using this approach for other age
groups in each year, eight birth cohorts (1972–77, 1966–71,
1960–65, 1954–59, 1948–53, 1942–47,1936-41,1930-35)
had three estimates of H. pylori seroprevalence at 6 year
intervals for 12 years.
Ethics statement
The protocol of this study was approved by the main
Institutional Review Board of Seoul National University
Hospital (IRB No. H-1011-038-339).
Results
Seroprevalence and eradication history of H. pylori in
total subjects
The seroprevalence of H. pylori was 52.8% (8,216/15,560)
after exclusion of H. pylori eradicated history in 19,272 eli-
gible subjects and 54.4% (5,882/10,796) after exclusion of
symptomatic subjects (Figure 1).
The demographics and clinical characteristics by group
are presented in Table 1.
Among the 19,272 subjects, 19.3% reported a history of
eradication therapy for H. pylori infection. By logistic re-
gression modeling, the influencing factors for having a his-
tory of eradication therapy for H. pylori infection were
male, older age, higher income, living in Seoul (Capital
area), the presence of GI symptom and GC family history
(Table 2).
Risk factors for H. pylori infection in asymptomatic
subjects without a history of H. pylori eradication
The risk factors for H. pylori infection in asymptomatic
subjects without a history of H. pylori eradication wereFigure 1 Study flowchart in 2011.significantly associated with gender, age, geographic area,
economic status, education level, and cholesterol level
(Table 3). Seropositivity of H. pylori was significantly lower
in females than in males (OR = 0.79, 95% CI = 0.71-0.87).
By age, seroprevalence increased in a nearly linear fashion
from 20 to 59 years of age. However, the prevalence
remained steady from 60 years of age. Regarding residence,
when compared with Seoul, other provinces except for
Gyeonggi and Kangwon had a higher risks of H. pylori
seropositivity. Subjects with high income and high educa-
tion level had a lower likelihoods of having H. pylori sero-
positivity. Subjects with a higher TC level (≥240 mg/dl)
had a 30% higher likelihood of having H. pylori seropositiv-
ity compared with subjects with a lower TC (<240 mg/dl)
(OR = 1.33, 95% CI = 1.14-1.54) after adjustments for BMI,
age, and income level. However, blood glucose level and
TG level did not affect the seropositivity of H. pylori infec-
tion after adjustment for other variables. Family history of
GC and BMI level did not affect the seropositivity of
H. pylori.
Comparison of seroprevalence of H. pylori among 2011,
2005, and 1998 in asymptomatic subjects without a
history of H. pylori eradication
Comparison of seroprevalence of H. pylori from 1998,
2005 and 2011 was performed, and the data from 1998
and 2005 were investigated by the Korean H. pylori Study
Group [10] and our group [9], respectively. The overall
seroprevalence of H. pylori infection was 54.4% (95% CI:
53.5-55.4%) in 2011 which is significantly decreased from
66.9 % (95% CI: 65.4-68.6%) in 1998, and 59.6 % (95% CI:
58.5-60.7%) in 2005 (p < 0.001) (Panel A of Figure 2).
There was a statistically significant reduction between
1998 and 2005, and between 2005 and 2011.




of H. pylori eradication
Asymptomatic subjects without
history of H. pylori eradication
n (%) n (%) n (%)
Total 19,272 (100.0) 15,560 (100.0) 10,796 (100.0)
Sex Male 10,557 (54.8) 8,311 (53.4) 6,085 (56.4)
Female 8,715 (45.2) 7,249 (46.6) 4,711 (43.6)
Subtotal 19,272 (100.0) 15,560 (100.0) 10,796 (100.0)
Age (years) 16-19 34 (0.2) 33 (0.2) 17 (0.2)
20-29 798 (4.1) 777 (5.0) 421 (3.9)
30-39 2,853 (14.8) 2,607 (16.8) 1,659 (15.4)
40-49 5,087 (26.4) 4,198 (27.0) 2,913 (27.0)
50-59 6,176 (32.0) 4,709 (30.3) 3,403 (31.5)
60-69 3,358 (17.4) 2,493 (16.0) 1,840 (17.0)
≥70 966 (5.0) 743 (4.8) 543 (5.0)
Subtotal 19,272 (100.0) 15,560 (100.0) 10,796 (100.0)
Geographic area Seoul 10,755 (55.8) 8,515 (54.8) 5,829 (54.0)
Gyeonggi 3,025 (15.7) 2,403 (15.5) 1,683 (15.6)
Chungcheong 863 (4.5) 740 (4.8) 536 (5.0)
Kyungsang 1,630 (8.5) 1,313 (8.4) 914 (8.5)
Cholla 1,807 (9.4) 1,553 (10.0) 1,194 (11.1)
Kangwon 588 (3.1) 466 (3.0) 331 (3.1)
Jeju 589 (3.1) 555 (3.6) 299 (2.8)
Subtotal* 19,257 (100.0) 15,545 (100.0) 10,786 (100.0)
Household income** low 2,114 (12.5) 1,838 (13.5) 1,247 (13.2)
medium 11,049 (65.2) 8,843 (65.1) 6,197 (65.6)
high 3,781 (22.3) 2,910 (21.4) 2,005 (21.2)
Subtotal* 16,944 (100.0) 13,591 (100.0) 9,449 (100.0)
Education level*** low 1,743 (9.5) 1,458 (9.9) 984 (9.7)
medium 3,667 (20.0) 3,004 (20.4) 1,981 (19.4)
high 12,928 (70.5) 10,250 (69.7) 7,223 (70.9)
Subtotal* 18,338 (100.0) 14,712 (100.0) 10,188 (100.0)
Body mass index (kg/m2) <18.5 840 (4.4) 736 (4.8) 412 (3.9)
18.5 - <23.0 7,696 (40.6) 6,245 (40.7) 4,237 (39.8)
23.0 - <25.0 4,818 (25.4) 3,821 (24.9) 2,759 (25.9)
≥25.0 5,625 (29.6) 4,530 (29.5) 3,249 (30.5)
Subtotal* 18,979 (100.0) 15,332 (100.0) 10,657 (100.0)
Cholesterol (mg/dl) <240 16,671 (90.5) 13,417 (90.4) 9,228 (90.1)
≥240 1,755 (9.5) 1,428 (9.6) 1,013 (9.9)
Subtotal* 18,426 (100.0) 14,845 (100.0) 10,241 (100.0)
TG (mg/dl) <150 14,651 (79.7) 11,873 (80.1) 8,118 (79.4)
≥150 3,736 (20.3) 2,941 (19.9) 2,102 (20.6)
Subtotal* 18,387 (100.0) 14,814 (100.0) 10,220 (100.0)
Glucose (mg/dl) <100 12,999 (70.7) 10,667 (72.0) 7,206 (70.5)
100 - <126 4,438 (24.1) 3,399 (22.9) 2,459 (24.1)
≥126 955 (5.2) 747 (5.0) 555 (5.4)
Subtotal* 18,392 (100.0) 14,813 (100.0) 10,220 (100.0)
Lim et al. BMC Gastroenterology 2013, 13:104 Page 4 of 10
http://www.biomedcentral.com/1471-230X/13/104
Table 1 Baseline characteristics of subjects (Continued)
Family history of gastric cancer No 16,470 (86.6) 13,418 (87.5) 9,473 (88.2)
Yes 2,556 (13.4) 1,910 (12.5) 1,270 (11.8)
Subtotal* 19,026 (100.0) 15,328 (100.0) 10,743 (100.0)
GI symptoms No 13,121 (68.8) 10,796 (70.3)
Yes 5,954 (31.2) 4,568 (29.7)
Subtotal* 19,075 (100.0) 15,364 (100.0)
*Subjects with missing values were excluded.
**Household income was classified as low (less than US $ 3,000), medium (US $ 3,000 to 10,000), or high (more than US $ 10,000).
***Education level was classified as low (middle school graduates or less), middle (high school graduates or university dropouts),
or high (university graduates or graduates of a postgraduate course).
GI gastrointestinal.
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a significant downward trend in most of areas over time ex-
cept in Kyungsang and Kangwon. (Panel B of Figure 2).
The seroprevalence of H. pylori and 95% CI at intervals




Sex Male 10,557 2,24
Female 8,715 1,46














Household income* Low 2,114 276
Medium 11,049 2,20
High 3,781 871
Education level** Low 1,743 285
Medium 3,667 663
High 12,928 2,67
GI symptoms No 13,121 2,32
Yes 5,954 1,38
Family history of gastric cancer No 16,470 3,05
Yes 2,556 646
*, **, GI, same as those of Table 1.
CI confidence Interval, Ref reference.
Total subject number of multivariable logistic regression was 16,770.Panel C of Figure 2. The seroprevalence of H. pylori was
decreased in the all age groups over time with statistical
significance from 1998 to 2011. A steep decreasing pattern
was observed for subjects under 40 years of age between
1998 and 2005. However, when the time period wasdication therapy




6 16.8 0.77 0.71 0.84
2.9 2.27 0.28 18.21
2.6 Ref
8.6 4.22 2.44 7.31
17.5 9.32 5.44 15.94
7 23.8 14.33 8.39 24.48
25.8 16.91 9.87 28.97
23.1 16.73 9.58 29.20
0 20.8 Ref
20.6 0.97 0.87 1.08
14.3 0.76 0.61 0.94
19.4 0.85 0.74 0.99
14.1 0.68 0.58 0.80
20.7 1.30 1.04 1.64
5.8 0.27 0.19 0.39
13.1 0.70 0.58 0.83
6 20.0 0.96 0.87 1.05
23.0 Ref
16.4 0.70 0.59 0.84
18.1 0.87 0.78 0.97
8 20.7 Ref
5 17.7 Ref
6 23.3 1.60 1.47 1.73
2 18.5 Ref
25.3 1.34 1.21 1.49
Table 3 Risk factors for H. pylori seropositivity in asymptomatic subjects without a history of H. pylori eradication and
gastric operation (Multivariable logistic regression)
Total H. pylori Seropositivity
N % Odds ratio 95% CI
Total 10,796 5,882 54.5
Sex Male 6,085 3,472 57.1 Ref
Female 4,711 2,410 51.2 0.79 0.71 0.87
Age (years) 16-19 17 2 11.8 0.55 0.11 2.68
20-29 421 111 26.4 Ref
30-39 1,659 698 42.1 1.55 1.18 2.04
40-49 2,913 1,531 52.6 2.39 1.83 3.11
50-59 3,403 2,088 61.4 3.52 2.70 4.60
60-69 1,840 1,134 61.6 3.57 2.70 4.71
≥70 543 318 58.6 3.11 2.24 4.31
Geographic area Seoul 5,829 2,917 50.0 Ref
Gyeonggi 1,683 898 53.4 1.07 0.95 1.21
Chungcheong 536 297 55.4 1.29 1.05 1.58
Kyungsang 914 595 65.1 1.29 1.06 1.57
Cholla 1,194 790 66.2 1.66 1.41 1.96
Kangwon 331 200 60.4 1.19 0.92 1.54
Jeju 299 176 58.9 1.36 1.05 1.77
Household Income* Low 1,247 785 63.0 1.21 1.00 1.45
Medium 6,197 3,416 55.1 1.07 0.96 1.19
High 2,005 1,042 52.0 Ref
Education** Low 984 629 63.9 1.01 0.84 1.23
Medium 1,981 1,165 58.8 1.13 1.00 1.28
High 7,223 3,779 52.3 Ref
Body Mass Index (kg/m2) <18.5 412 180 43.7 1.03 0.81 1.31
18.5 - <23.0 4,237 2,224 52.5 Ref
23.0 - <25.0 2,759 1,565 56.7 0.98 0.88 1.10
≥25 3,249 1,830 56.3 0.95 0.84 1.06
Cholesterol (mg/dl) <240 9,228 4,882 52.9 Ref
≥240 1,013 624 61.6 1.33 1.14 1.54
Triglyceride (mg/dl) <150 8,118 4,316 53.2 Ref
≥150 2,102 1,179 56.1 0.98 0.87 1.10
Glucose (mg/dl) <100 7,206 3,786 52.5 Ref
100 − <126 2,459 1,378 56.0 0.93 0.84 1.04
≥126 555 328 59.1 0.98 0.80 1.19
Family history of gastric cancer No 9,473 5,152 54.4 Ref
Yes 1,270 700 55.1 0.96 0.84 1.09
*, **, GI, CI, Ref, same as those of Table 2.
Total subject number of multivariable logistic regression was 8,688.
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in older age groups, resulting in an overall decrease for all
age groups.
The birth cohort effects
To observe lifetime trends, the seroprevalence of H.
pylori of categorized birth cohorts against age were plot-
ted as shown in Figure 3. Each line connects the valuesfor the same cohort-group in different age groups. For
example, a line first represents a birth cohort of 1972–
77 in all graphs. At the same age of 28–33 years (mean
30.5 years old), a younger birth cohort of 1972–77 had a
lower seroprevalence of H. pylori when compared with a
older birth cohort of 1966–71. Likewise, all younger
birth cohorts at the same age had a lower seroprevalence
of H. pylori compared with older birth cohorts. Within
Figure 2 Trends of seroprevalence of H. pylori infection in asymptomatic subjects without a history of H. pylori eradication in 1998
[10], 2005 [9], and 2011. (*p < 0.05) Seroprevalence by sex (Panel A), by geographic area (Panel B) and by age (Panel B).
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ing pattern of seropositivity of H. pylori except for a
birth cohort of 1972–1977. This birth cohort showed a
decreasing pattern from 22–27 to 28–33 years of age,
but it showed a very slight increase (from 41% to 43%)
from 28–33 to 34–39 years of age.
Discussion
The decreasing trend (from 66.9% to 54.4%) of seropreva-
lence of H. pylori over 13 years was explained by birth co-
hort analysis, and a relationship between H. pylori infection
and high cholesterol level was found in this large cohort.
A drop in the seroprevalence of H. pylori infection has
been observed in previous studies [2,3,13]. This trend
was most often explained by a combination of various
factors including rapid economic growth, improved sani-
tation, and widespread use of antibiotics and proton
pump inhibitors [2,3]. Similarly, the overall seropreva-
lence of H. pylori significantly decreased in the last sur-
vey of the Korean population in 2005 [9] compared withthat in 1998 [10], but the declining trend was different
depending on the age groups and areas. Although the
drop in H. pylori infection was bigger in younger age
groups of subjects 40 years old or less for seven years
from 1998 to 2005, the difference of seroprevalence in
older groups during same periods was smaller, as shown
in the upper two lines of figure 2C. In addition, regard-
ing areas, only subjects who lived in Seoul (capital) and
Gyeonggi province which surrounds the capital, showed
a clear declining trend during the same periods, but not
in all districts in previous study [9]. Furthermore, sub-
jects who lived in Chungcheong province showed a
slight increase between 1998 and 2005.
However, when we extended the time period to 2011 in
this study, this decreasing trend was more prominent for
all ages over 13 years. Similarly, a Japanese study of
seropositivity trends of H. pylori over a period of 10
years from 1992 to 2002–2006 also found declining
trends of seropositivity for all age groups [13]. Regard-
ing province, there was no increasing pattern in any
Figure 3 Seroprevalence of H. pylori infection in asymptomatic subjects without a history of H. pylori eradication in birth cohort
against age. Each line connects the values for the same cohort-group in different age group. For example, the first line shows the
seroprevalence of H. pylori in a birth cohort of 1972–77 for ages of 22–39 years, and the second line shows the seroprevalence of H. pylori in a
birth cohort of 1966–71 for ages of 28–45 years. All younger birth cohorts at the same age have a lower seroprevalence of H. pylori than older
birth cohorts.
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was observed in all provinces except two provinces,
Kyungsang and Kangwon areas.
We also analyzed birth cohort effects. In the cross
sectional study, the prevalence of H. pylori infection in-
creased till 40 – 49 years of age, after which it remained
steady. When we graphically drew the prevalence in
H. pylori infection by birth cohort to differentiate the
increase of infection during aging, the seroprevalence
was lower in younger birth cohort (i.e. people who were
born later) than the older birth cohort (people who were
born earlier) at the same age, showing a clear cohort
effect in subjects up to 40–45 years of age. This
phenomenon could be explained by continuous influx
of younger birth cohorts [7]. A similar birth cohort ef-
fect for H. pylori infection was observed in Western
studies [2,3,7,8]. In addition, H. pylori infection in
adults is mostly acquired by the age of 15 years [7,8].
One study which followed children (1–3 years old) for
21 years indicated that the annual seroconversion rate
had a highest risk at the age of 4–5 years, and newly ac-
quired H. pylori infections mostly occurred by the age
of 10 years [14]. However, there is a doubt whether only
a birth cohort effect could explain this pattern. That is,
one study in Canada mentioned that an increasing pat-
tern of H. pylori infection with advancing age may be
due to the continuous risk of infection in adults rather
than cohort effects [6]. The decrease of H. pylori sero-
prevalence with advancing age within the same birth
cohort in our study strongly suggests that aging is not
likely to raise risk of H. pylori infection. There was adecreasing effect with advancing age within the same
birth cohorts. This might have occurred as a result of
cases taking antibiotics or proton pump inhibitors even
without formal eradication therapy of H. pylori [15].
There have been several studies regarding risk factors
of H. pylori infection [9,14,16-18], but their results are
still unclear, except socioeconomic status as the risk fac-
tors. Our results also showed that lower social eco-
nomic status is associated with the risk of H. pylori
infection in a cross sectional analysis. Furthermore, sub-
jects with lower social economic status had a lower like-
lihood of taking H. pylori eradication therapy in the
present study. Interestingly, our study showed a rela-
tionship between cholesterol level and seropositivity of
H. pylori. Subjects who had a TC level of ≥240 mg/dl
were 1.3 times more likely to be seropositive for H. pyl-
ori. In frequency analysis, higher levels of TG and glu-
cose as well as TC were also associated with H. pylori
infection, but after adjusting for demographic variables,
clinical information, and socioeconomic status(i.e. age,
BMI, income and etc.), only TC among metabolic pa-
rameters was related to H. pylori infection. So far, the
results regarding the relationship between lipid parame-
ters such as TC, TG and low-density lipoprotein choles-
terol (LDL-C) levels and H. pylori seropositivity have
not been consistent. Some studies [19-21] reported no
relationship, but several studies reported higher athero-
genic lipid parameter levels in H. pylori seropositive
subjects in comparison with seronegative ones [22-24]
as seen in the present study. Our study results could be
convincing for demonstrating the effect of H. pylori
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relationship between TC and H. pylori seropositivity
was persistent even after adjustment for BMI and age in
a large cohort. The mechanism of how H. pylori infec-
tion modifies the serum lipid profiles is still not clear,
but a plausible explanation is that systemic inflamma-
tory response to the bacterium induces changes in lipid
and lipoprotein metabolism [25]. That is, chronic
H. pylori infection has been postulated to shift the lipid
profile toward an atherogenic direction via the action of
proinflammatory cytokines, such as interleukins 1 and
6, interferon-alpha, and tumor necrosis factor-alpha.
These cytokines are capable of affecting lipid metabol-
ism in various ways, including activation of adipose
tissue lipoprotein lipase, stimulation of hepatic fatty
acid synthesis, influencing lipolysis and the increasing
hepatic HMG-CoA reductase activity [26,27]. Thus, H.
pylori infection could play a role in the atherosclerotic
process and may be a reliable indicator for the assess-
ment of cardiovascular disease risk.
There are several limitations which should be ac-
knowledged in this study. First, the relationship be-
tween H. pylori infection and its risk factors in the
cross sectional study could not be proven conclusively.
However, this is an unavoidable limitation in the cross
sectional study. Second, we compared the time trends
of seroprevalence of H. pylori using two previous stud-
ies [9,10]. However, the responsible author (N.K.) did
play main role in these previous studies, and the popu-
lation in 2011 study was restricted to have comparabil-
ity of H. pylori seroprevalence. In other words, the
subjects in 2011 study were restricted to asymptomatic
people without a history of H. pylori eradication and GI
operation. Moreover, this study was carried out nation-
wide, so our findings represent a national trend, not a
local phenomenon. Nonetheless, the study subjects in
1998 involved a relatively lower population from Seoul
and Gyeonggi, (capital city and its near city) compared
with the population in 2005 and 2011. Generally people
in capital cities have higher socioeconomic conditions
than those living in other areas. It may account for
much higher seroprevalence in 1998 compared with
2005/2011. However, the change of seroprevalence by
the strata (e.g. age, sex, region, etc.) over time periods
may indicate that our overall result is not much
influenced by a different proportion of subjects from
provinces. Third, for the generation of synthetic cohort,
cross-sectional data should have the same interval.
However, our data did not have the same interval as the
previous data. This is the reason why we considered the
data from 1998 as equivalent to those from 1999. This
intentional modification could have caused bias, but we
think that the bias may be negligible because H.pylori
seroprevalence was not changed much by one-year.Conclusion
In conclusion, we confirmed that the seropositivity of H.
pylori declined across all age groups from 1998 to 2011
using nationwide data, an effect which originated from
birth cohort effects and continuous risk reduction of H.
pylori infection during one’s life time. In addition, we
found that high TC level as well as lower social eco-
nomic status had a relationship with H. pylori infection.
These results may suggest the importance of manage-
ment of H. pylori infection in younger age and the effect
of H. pylori infection on atherosclerosis.
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